11C-Acetate PET/CT Non-FDG-Avid Tumors
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00687778|
Recruitment Status : Unknown
Verified May 2008 by Tel-Aviv Sourasky Medical Center.
Recruitment status was: Recruiting
First Posted : June 2, 2008
Last Update Posted : June 2, 2008
F18-FDG is the widely used PET tracer in the routine practice of oncologic disease imaging using the technology of PET-CT. However, FDG-avidity is a characteristic of the individual tumor. There are various types of human malignancies, which are not taking FDG in access. In these cases FDG is not a sensitive tracer of imaging. In search for other tumor PET tracers, C11-Acetate has been shown recently in a few early studies to have a potential value in imaging of non-FDG-avid tumors.
The purpose of the current study is to assess the role of 11C-acetate PET in various tumors, which often are not detected by 18F-FDG and were not widely assessed until now.
|Condition or disease|
|Soft Tissue Sarcomas Thyroid Cancer Lung Cancer Indolent Lymphoma Neuroendocrine Tumors GIST Uterine Malignancies Carcinoma, Hepatocellular Carcinoma, Lobular Teratoma|
Recent publications have suggested the use of 11C-acetate as another PET tracer for tumor imaging. The accumulation of 11C-acetate in tumor cells is related to the highly active lipid metabolism in the cell membrane associated with tumor growth. 11C-acetate is channeled into the tricarboxylic acid cycle via acetyl coenzyme A and then incorporated via phosphatidylcholine into the cell membrane's phopholipids. Possible biochemical paths of acetate incorporation or accumulation include (a) entering the Krebs cycle from acetyl coenzyme A (acetyl CoA) or as an intermediate metabolite, (b) esterification to form acetyl CoA as a major precursor in ß-oxidation for fatty acid synthesis, (c) combining with glycine in heme synthesis, and (d) through citrate for cholesterol synthesis. Of all of these possible metabolic pathways, participation in free fatty acid (lipid) synthesis is believed to be the dominant method of incorporation in tumors.
The clinical data on the role of 11C-acetate PET in human tumors is being accumulated. Most clinical studies have investigated the role of 11C-acetate PET in detection of prostate cancer. 11C-acetate PET was found valuable in the detection of recurrent prostate cancer, both in the prostate bed, lymph nodes and distant metastases. The main advantage of 11C-acetate is that it does not show physiological accumulation in the urinary bladder as is the case with 18F -FDG and therefore may be appropriate for the detection of active pelvic disease.
Comparing the uptake of 18F-FDG and of 11C-acetate in patients with lung carcinoma, the latter was found superior in the identification of a bronchiolo-alveolar carcinoma which often show no intense FDG uptake.
In the case of hepatic masses, well-differentiated HCC tumors were detect by 11C-acetate while poorly differentiated types were detected by 18F-FDG.
These data suggest that 11C-acetate PET may be valuable in the detection of well-differentiation slow growing tumors and may have a complementary role to the routinely used 18F-FDG.
|Study Type :||Observational|
|Estimated Enrollment :||100 participants|
|Study Start Date :||May 2008|
|Estimated Primary Completion Date :||June 2009|
|Estimated Study Completion Date :||June 2010|
100 patients with newly diagnosed tumors, which are often non-FDG avid or show only low intensity uptake: Soft tissue sarcomas, well-differentiated thyroid cancer, well-differentiated and bronchoalveolar lung cancer, indolent lymphomas, neuroendocrine tumors, GIST, uterine malignancies, mucin-producing cancer, teratoma, hepatoma, HCC and lobular breast carcinoma.
- Uptake of C11-Acetate and F18-FDG in tumor will be measured in SUV PET units [ Time Frame: At completion of acuisition ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00687778
|Contact: Einat Even-Sapir, MD, PhDemail@example.com|
|Department of Nuclear Medicine, Tel Aviv Sourasky Medical Center||Recruiting|
|Tel Aviv, Israel, 64239|
|Contact: Einat Even-Sapir, MD, PhD 972-3-697-3536 firstname.lastname@example.org|
|Contact: Limor Zuriel, MSc 972-3-697-3536 email@example.com|
|Principal Investigator:||Einat Even-Sapir, MD, PhD||Tel-Aviv Sourasky Medical Center|